Publications by authors named "Yalan Hao"
Unlabelled: Imatinib mesylate (IM) has revolutionized the treatment of gastrointestinal stromal tumor (GIST). However, most patients inevitably acquire IM resistance. Second- and third-line treatments exhibit modest clinical benefits with a median time to disease progression of 4 to 6 months, highlighting the urgency for novel therapeutic approaches.
View Article and Find Full Text PDFArticle Synopsis
- * Phosphorylation, regulated by kinases and phosphatases, is key in the process of DSB repair, with a balance between their activities being crucial for maintaining genomic stability.
- * Research highlights the importance of understanding kinases and phosphatases in DSB repair, as this knowledge could lead to new cancer therapies targeting these proteins.